Lv41
770 积分 2025-06-05 加入
Albuminuria in Patients with Morbid Obesity and the Effect of Weight Loss Following Bariatric Surgery
1小时前
待确认
Targeting Inflammation to Reduce Residual Cardiovascular Risk
2小时前
待确认
Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
1天前
待确认
GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice
2天前
已完结
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
4天前
已完结
Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial
5天前
已完结
Association between metabolic multimorbidity and the risk of cardiovascular disease, kidney disease, and mortality: longitudinal evidence from CHARLS (2011–2020)
12天前
已完结
GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease
12天前
已完结
Semaglutide: First Global Approval
13天前
已完结
GLP-1-based therapies for diabetes, obesity and beyond
14天前
已完结
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
2个月前
已采纳
Research Summary Neoadjuvant GOLP in Intrahepatic Cholangiocarcinoma
2个月前
已采纳
Research Summary Neoadjuvant GOLP in Intrahepatic Cholangiocarcinoma
2个月前
已驳回
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
2个月前
已撤回
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2个月前
已采纳
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
2个月前
已采纳
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
2个月前
已采纳
Floppy Eyelid Syndrome
3个月前
已采纳
Beta-Blockers after Myocardial Infarction — Toward Personalized Management
3个月前
已采纳
Elective Cesarean Section for Maternal Preference
3个月前
已采纳
皖公网安备34019202002308
